Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measures-Reference-Cited by-同舟云学术

Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measures

Published:2022-03-02 Issue:3 Volume:198 Page:431-442
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eyre Toby A.¹,Jensen Paw²^ORCID,Booth Stephen³,El‐Galaly Tarec Christoffer²⁴^ORCID

Affiliation:

1. Department of Haematology, Haematology and Cancer Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK

2. Department of Haematology, Clinical Cancer Research Centre Aalborg University Hospital Aalborg Denmark

3. Department of Haematology Royal Berkshire Hospital NHS Foundation Trust Reading UK

4. Department of Clinical Medicine Aalborg University Aalborg Denmark

Funder

Danish Cancer Society Research Center

NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

National Institute for Health Research

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18104

Reference63 articles.

1. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

2. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study

3. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

4. JohnsonP FedericoM KirkwoodA FossåA BerkahnL CarellaA et al.Adapted treatment guided by interim PET‐CT scan in advanced Hodgkin's lymphoma.2016;374(25):2419–29. Available from:https://pubmed.ncbi.nlm.nih.gov/27332902/

5. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone damage and health-related quality of life in Hodgkin lymphoma survivors: closing the gaps;Frontiers in Oncology;2024-02-09

2. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study);JCO Global Oncology;2024-02

3. Risk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia—A nationwide population‐based study;British Journal of Haematology;2024-02

4. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study;British Journal of Haematology;2023-11-13

5. Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study;BMJ Supportive & Palliative Care;2023-03-16